About alkermes plc - ALKS
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.
ALKS At a Glance
Alkermes Plc
Connaught House
Dublin, Dublin 4
| Phone | 353-1-772-8000 | Revenue | 1.48B | |
| Industry | Pharmaceuticals: Major | Net Income | 241.66M | |
| Sector | Health Technology | Employees | 2,050 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ALKS Valuation
| P/E Current | 112.935 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 19.538 |
| Price to Sales Ratio | 3.199 |
| Price to Book Ratio | 2.547 |
| Price to Cash Flow Ratio | 9.07 |
| Enterprise Value to EBITDA | 12.351 |
| Enterprise Value to Sales | 2.352 |
| Total Debt to Enterprise Value | 0.02 |
ALKS Efficiency
| Revenue/Employee | 719,950.732 |
| Income Per Employee | 117,884.878 |
| Receivables Turnover | 4.419 |
| Total Asset Turnover | 0.644 |
ALKS Liquidity
| Current Ratio | 3.55 |
| Quick Ratio | 3.188 |
| Cash Ratio | 2.428 |
ALKS Profitability
| Gross Margin | 86.31 |
| Operating Margin | 17.207 |
| Pretax Margin | 19.747 |
| Net Margin | 16.374 |
| Return on Assets | 10.54 |
| Return on Equity | 14.716 |
| Return on Total Capital | 12.791 |
| Return on Invested Capital | 14.145 |
ALKS Capital Structure
| Total Debt to Total Equity | 3.848 |
| Total Debt to Total Capital | 3.705 |
| Total Debt to Total Assets | 2.766 |
| Long-Term Debt to Equity | 3.477 |
| Long-Term Debt to Total Capital | 3.348 |